Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell MalignanciesRanjana H. Advani, Nathan Fowler, Joseph J. Buggy et al.|Journal of Clinical Oncology|2012Cited by 1.1k
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myelomaBruno Paiva, María‐Teresa Cedena, Diego Alignani et al.|Leukemia|2020Cited by 47
The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II TrialLühua Wang, André Goy, Peter Martin et al.|Blood|2011Cited by 41